Panel Tells Canadian Govt A Subscription-Style Pull Incentive Is Needed To Tackle AMR
An expert panel formed by the Council of Canadian Academies says drug developers that provide “novel, valuable antibiotic solutions” should be rewarded with a “fair and reasonable guaranteed revenue” for their drugs.
You may also be interested in...
Governments should increase financial resources for novel antimicrobial drug candidates in the later stages of development and tackle shortages of existing, underused antibiotics to combat antimicrobial resistance, says a new report from the OECD.
Melinta CEO and a representative of the Infectious Diseases Society of America call on a Senate HELP subcommittee to push for passage of PASTEUR Act. Introduced in the Senate and House for the third time this year, the measure would establish a subscription model to pay drug developers upfront for certain antimicrobials.
The National Health Service is seeking feedback on its plans to expand its pioneering subscription-style drug contracts to develop lifesaving antibiotics and tackle the problem of antimicrobial resistance.